Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Pallas Capital Advisors LLC

Pallas Capital Advisors LLC trimmed its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 84.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,215 shares of the medical equipment provider's stock after selling 17,848 shares during the period. Pallas Capital Advisors LLC's holdings in Hologic were worth $260,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of HOLX. Cetera Investment Advisers lifted its stake in Hologic by 188.9% in the first quarter. Cetera Investment Advisers now owns 20,464 shares of the medical equipment provider's stock valued at $1,595,000 after buying an additional 13,380 shares during the last quarter. Nordea Investment Management AB boosted its stake in Hologic by 1.3% during the 1st quarter. Nordea Investment Management AB now owns 1,507,743 shares of the medical equipment provider's stock worth $116,797,000 after purchasing an additional 19,680 shares during the period. Clearbridge Investments LLC grew its position in Hologic by 51.4% during the 1st quarter. Clearbridge Investments LLC now owns 518,596 shares of the medical equipment provider's stock worth $40,430,000 after purchasing an additional 176,006 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its stake in Hologic by 18.3% in the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,184,427 shares of the medical equipment provider's stock valued at $170,297,000 after purchasing an additional 338,212 shares during the period. Finally, Mediolanum International Funds Ltd purchased a new stake in shares of Hologic in the first quarter valued at about $1,793,000. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Hologic Trading Up 1.8 %

Shares of HOLX stock traded up $1.46 during mid-day trading on Friday, hitting $82.33. 1,955,998 shares of the company's stock were exchanged, compared to its average volume of 1,574,248. The stock has a market cap of $19.12 billion, a price-to-earnings ratio of 28.00, a PEG ratio of 2.94 and a beta of 0.98. The company has a quick ratio of 3.32, a current ratio of 3.99 and a debt-to-equity ratio of 0.51. Hologic, Inc. has a fifty-two week low of $66.53 and a fifty-two week high of $84.67. The stock has a 50-day simple moving average of $80.99 and a two-hundred day simple moving average of $77.98.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on HOLX. Citigroup cut Hologic from a "buy" rating to a "neutral" rating and dropped their price target for the company from $95.00 to $85.00 in a research report on Tuesday, October 1st. StockNews.com downgraded Hologic from a "strong-buy" rating to a "buy" rating in a research note on Friday, September 27th. Mizuho increased their price target on shares of Hologic from $85.00 to $90.00 and gave the company an "outperform" rating in a research report on Friday, October 4th. Stephens reissued an "overweight" rating and set a $92.00 price objective on shares of Hologic in a research note on Tuesday, July 30th. Finally, JPMorgan Chase & Co. upped their target price on Hologic from $91.00 to $95.00 and gave the company an "overweight" rating in a research note on Tuesday, July 30th. Five equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $87.50.

Insider Buying and Selling

In related news, insider Brandon Schnittker sold 476 shares of the firm's stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total value of $39,560.36. Following the sale, the insider now directly owns 3,735 shares of the company's stock, valued at approximately $310,415.85. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.75% of the stock is currently owned by company insiders.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.